CTIP2 Expression in Human Head and Neck Squamous Cell Carcinoma Is Linked to Poorly Differentiated Tumor Status by Ganguli-Indra, Gitali et al.
CTIP2 Expression in Human Head and Neck Squamous
Cell Carcinoma Is Linked to Poorly Differentiated Tumor
Status
Gitali Ganguli-Indra
1*, Christine Wasylyk
4,5, Xiaobo Liang
1, Regine Millon
2, Mark Leid
1,3, Bohdan
Wasylyk
4,5, Joseph Abecassis
2, Arup Indra
1,3*
1Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon, United States of America, 2Centre Paul Strauss, Strasbourg,
France, 3Environmental Health Sciences Center, Oregon State University, Corvallis, Oregon, United States of America, 4IGBMC, Inserm U596 and CNRS UMR 7104, Illkirch,
France, 5Universite ´ Louis Pasteur, Strasbourg, France
Abstract
Background: We have demonstrated earlier that CTIP2 is highly expressed in mouse skin during embryogenesis and in
adulthood. CTIP2 mutant mice die at birth with epidermal differentiation defects and a compromised epidermal
permeability barrier suggesting its role in skin development and/or homeostasis. CTIP2 has also been suggested to function
as tumor suppressor in cells, and several reports have described a link between chromosomal rearrangements of CTIP2 and
human T cell acute lymphoblast leukemia (T-ALL). The aim of the present study was to look into the pattern of CTIP2
expression in Head and Neck Squamous Cell Carcinoma (HNSCC).
Methodology/Principal Findings: In the present study, we analyzed CTIP2 expression in human HNSCC cell lines by western
blotting, in paraffin embedded archival specimens by immunohistochemistry (IHC), and in cDNA samples of human HNSCC
by qRT-PCR. Elevated levels of CTIP2 protein was detected in several HNSCC cell lines. CTIP2 staining was mainly detected in
the basal layer of the head and neck normal epithelium. CTIP2 expression was found to be significantly elevated in HNSCC
(p,0.01), and increase in CTIP2 expression was associated with poorly differentiated tumor status. Nuclear co-localization of
CTIP2 protein and cancer stem cell (CSC) marker BMI1 was observed in most, if not all of the cells expressing BMI1 in
moderately and poorly differentiated tumors.
Conclusions/Significance: We report for the first time expression of transcriptional regulator CTIP2 in normal human head
and neck epithelia. A statistically significant increase in the expression of CTIP2 was detected in the poorly differentiated
samples of the human head and neck tumors. Actual CTIP2, rather than the long form of CTIP2 (CTIP2L) was found to be
more relevant to the differentiation state of the tumors. Results demonstrated existence of distinct subsets of cancer cells,
which express CTIP2 and underscores the use of CTIP2 and BMI1 co-labeling to distinguish tumor initiating cells or cancer
stem cells (CSCs) from surrounding cancer cells.
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Introduction
Head and neck squamous cell cancers (HNSCC) are the sixth
most common cancers in the world and are a major cause of
significant morbidity. In the United States alone, Head and neck
cancers account for less than 5% of all cancers and for less than
3% of all cancer deaths. For cancers of the oral cavity and pharynx
alone 35,310 new cases and 7,590 deaths are estimated for 2008
[1,2]. Although, HNSCC has been linked to tobacco and betel nut
use, alcohol consumption, frequent mouthwash use, exposure to
human papillomavirus (HPV), and people with history of smoking
and alcohol use are at a greater risk [2,3]. Genetics and other risk
factors may also be associated with the pathogenesis of the disease.
New approaches in the treatment of locally advanced HNSCC
include chemotherapy and curative treatment to achieve organ
preservation and to improve overall survival [4]. Inspite of
advances in surgical and other treatments that enhance quality
of life and moderating pain, survival rates are not improving for
this type of cancer [5,6]. There has been no significant
improvement in 5-year survival over the past 20 years, despite
aggressive and multidisciplinary treatment approaches [7,8,9].
Research on Molecular biology has provided us with large number
of biomarkers that can provide information related to prognosis,
treatment options, recurrence and development of secondary
primary tumor [10]. Although biomarkers like human papilloma-
virus (HPV) and EGFR are well studied, their use in therapeutics is
still not exploited successfully for efficient management of head
and neck cancer [10]. New techniques are being developed to
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expand our knowledge of the biology of these cancers. Basic
research efforts in terms of identifying novel genes with an altered
expression pattern and having a role in critical biological processes
such as proliferation and differentiation, disease progression and
metastasis of tumors are needed to facilitate the diagnosis,
prognosis and therapy of HNSCC patients.
Chicken ovalbumin upstream promoter-transcription factor
(COUP-TF)-interacting protein 2 (CTIP2, Bcl11b) is a transcrip-
tional regulator (zinc finger protein) that functions by direct,
sequence-specific DNA binding activity or by recruitment to the
promoter template by interaction with COUP-TF family member
[11,12,13,14]. The CTIP2 gene (both mouse and human) contains
4 exons and the majority of the CTIP2 open reading frame is
encoded by exon 4. Kominami’s group has reported two
alternatively spliced transcript variants, which encode distinct
isoforms called CTIP2 long (containing exon1, 2,3 and 4) and
CTIP2 short (lacking exons 2 and 3), [15]. Actual CTIP2 is the
one lacking exon 3. SK-N-MC human neuroblastoma cells and
Jurkat cells are known to endogenously express two splice variants
of CTIP2 with a molecular weight of 95.5 and 88.5 kDa,
respectively [14,16]. Bcl11b has been suggested to function as
tumor suppressor in cells, primarily based on human loss of
homozygosity (LOH) studies. Several reports have described a link
between chromosomal rearrangements of CTIP2 and human T
cell acute lymphoblastic leukemia (T-ALL) [17]. An association
between p53 and CTIP2 in mice has been implicated in the
development of thymic lymphomas [15] and the amplification
and/or translocation of CTIP2 is thought to play a role in human
leukemogenesis [18]. Recently, it has been shown that CTIP2 is
expressed early during mouse development as well as in the adult
animal, and in both cases, expression is most predominant in the
skin/epithelial structures, CNS and thymus [19,20]. Mice lacking
CTIP2 die at birth and exhibit epidermal differentiation defects
and a compromised epidermal permeability barrier [21]. More-
over, CTIP2 expression in adult wild type mouse skin was
observed to increase dramatically during wound healing, and in
pathological conditions particularly in the proliferating cells of the
wound bed (Ganguli-Indra et al., unpublished work). Taken
together, these results demonstrate that CTIP2 could be of
potential importance in human health and highlight the need for
additional information regarding their function and expression
patterns in pathological diseases and cancer. Since CTIP2 was
upregulated in our wound healing experiments and as wound
healing and cancer have key similarities where cancer is defined as
‘‘wound that never heals’’ [22], we were interested to look at CTIP2
expression in HNSCC. The main aim of this work is to understand
the cellular and molecular basis of CTIP2 overexpression in
HNSCC and to establish it as a novel biomarker in human
HNSCC. In this study, we have determined CTIP2 expression in
several human normal, and HNSCC cell lines. We also evaluated
CTIP2 expression pattern by immunohistochemistry (IHC) and
qRT-PCR, and determined correlation between clinicopatholog-
ical factors and CTIP2 expression in a panel of human HNSCC
samples.
Materials and Methods
Tissue samples
Paraffin embedded tissue sections from 40 different Head and
neck tumors for immunohistochemistry, cDNA samples from 28
head and neck tumor and 10 normal uvula cDNA samples for
qRT-PCR (normal uvulas were obtained from patients surgically
treated for head and neck cancer and were at least 2 cm. away
from the tumor lesion) were obtained following Institutional review
board (‘‘Comite ´ de recherche clinique du Centre Paul Strauss.’’
(Pre ´sident: Pr Patrick DUFOUR) approval. Informed written
consents were obtained from patients undergoing surgery as a
primary treatment, without previous radiation or chemotherapy.
The tumors were classified according to TNM stage (tumor, node,
metastasis) based on the UICC criteria (Sobin LH, Wittekind C,
1997, TNM classification of malignant tumors. New York. Willey-Liss,
Inc.). Histopathological differentiation status was defined depend-
ing on the degree of keratin pearl formation, keratinization, overall
resemblance to normal squamous epithelium, according to WHO
criteria [WHO. Histological typing of upper respiratory tract tumors.
K.Shanmugaratnam and LH Sobin (eds.). International Histological
Classification of Tumors. 1978, Vol. 19. Springer-Verlag (Geneva)].
Normal samples were collected from the farthest margin of the
surgical resections (uvula). All the above mentioned samples were
obtained from our collaborator Joseph Abecassis, Centre Paul
Strauss, Strasbourg, France.
Histopathological features of HNSCC
Legends for:
Differentiation status
1: well-differentiated
2: moderately differentiated
3: poorly differentiated (Poorly differentiated tumors are the less
differentiated squamous cell carcinomas).
4: undifferentiated (correspond to epithelial neoplasms without
evidence of squamous or glandular differentiation)
T size
1=T1, tumor 2 cm. or less in greatest dimension
2=T2, tumor 2 cm. and 4 cm.
3=T3, tumor 4c m
4=T4, tumor invades adjacent structures
Tumor Staging
Stage I : T1N1M0
Stage II: T2N0M0
Stage III : T3N0M0,
T1,T2,T3,N1M0
Stage IV : T4N0,N1M0
Any T, N2, N3, M0
Any T, any N, M
Immunohistochemistry. Formalin-fixed and paraffin-
embedded HNSCC sections were used in our studies. The
sections were deparaffinized in xylene, dehydrated through
graded alcohols, and placed in 0.1% hydrogen peroxide to
quench any endogenous peroxidase activity. A 5 minute, 750 W
microwave pretreatment in citrate buffer (pH 6.0) was repeated 4
times and followed by treatment with 10% normal rabbit serum
for 30 minutes. to block nonspecific antibody binding. The slides
were then incubated with a rat CTIP2 monoclonal antibody, 1/
300 dilution (Abcam product number 18465; clone 25B6) in a
humid chamber at 4uC overnight. Secondary antibody staining
was carried out with a biotin-labeled rabbit anti-rat antibody 1/
500 dilution (Jackson Immuno Research Laboratories, INC,
catalogue number: 112-065-143) for 2 hrs. at 37uC, followed by
incubation with a streptavidin-biotin horseradish peroxidase
complex (Vector Laboratories, catalog number: SA-5704).
CTIP2 Expression in HNSCC
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substrate kit, SK-4100) for 10 minutes. Counterstaining them with
Mayer hematoxylin before dehydration and mounting. We
analyzed the expression of CTIP2 by comparing the staining
intensities between the different samples with and without addition
of primary antibody. The staining intensities which were
compared were done in the same time and under same
conditions. We performed the staining experiment several times
and the results were consistent. The analyses of CTIP2 expression
were independently performed by two investigators. Staining
intensities for each section were as followed: 0, no staining; 1 weak
staining; 2 moderate staining; and 3 strong staining. A tumor was
considered CTIP2-positive if more than 10% of the tumor cells
demonstrated positive nuclear staining.
For immunofluorescence co-staining studies, paraffin sections
were rehydrated asdescribed aboveand processed as described [19].
Slides were then incubated overnight in a humidified chamber with
CTIP2 and BMI1 (Abcam: ab14389, 1/100), cytokeratin 10
(Abcam: ab9026, 1/100, ) and Ki-67 (Abcam: ab15580, 1/200)
primary antibodies. Primary antibody incubation was followed by
three washes with PBST and incubation with fluorescently-labeled
[Cy2 (1:250) or Cy3 (1:500) (Jackson ImmunoResearch)] secondary
antibody for 2 hours. Nuclei were counterstained with DAPI.
Finally, sections were rinsed with PBST, dehydrated through
sequential washes in 50%, 70%, 95%, and 100% ethanol and then
cleared in xylene. Slides were mounted with DPX mounting media
and allowed to dry overnight. Images were captured at 406
magnification using Leica DMRA fluorescent microscope and
Hamamatsu C4742-95 digital camera and processed using Open-
Lab software and Adobe Photoshop 7.0.
Cell culture and Western blotting. Cells were freshly
thawed, cultured in their respective medium using the 3T3
protocol. When the cells reached 75 to 80% confluency we change
the medium and the next day the cells were harvested and lysed in
Laemmli buffer containing a protease inhibitor cocktail
(Complete; Roche) and 5 mM Dithiothreitol and boiled. The
whole-cell extracts (20 mg protein) were subjected to SDS-PAGE
and electro-blotted to nitrocellulose membranes. The membranes
were blocked in 5% non-fat dry milk in 10 mM Tris–HCl, pH 7.8,
150 mM NaCl, 0.1% Tween 20, and incubated overnight with the
rat monoclonal 25B6 to CTIP2 diluted 1/1000 in the blocking
buffer and developed using Super Signal West Pico
Chemiluminescent Substrate (Thermo scientific Pierce).
Cell lines used in this study
N GM 193: lymphoblast, normal EBV transformed (NIGMS
Human Genetic Mutant Cell Repository)
N HUVEC: umbilical cord, endothelium, normal (ATCC CRL-
1730)
N GM 3348: skin, normal fibroblasts (NIGMS)
N HS677Tg Fibroblasts, tongue, normal (ATCC CRL-7408)
N Hek-a: Primary human epidermal keratinocytes from adult
skin (HEKa, SKU# C-005-5C, Cascade)
N Hacat: Spontaneously immortalized non-tumorigenic human
skin keratinocytes (IGBMC cell culture service, DKFZ)
N SCC4: human squamous cell carcinoma, tongue (ATCC
CRL-1624)
N Cal27: squamous cell carcinoma, tongue (IGBMC cell culture
service, Dr Merlin)
N SCC25: human squamous cell carcinoma, tongue (ATCC
CRL-1628)
N SCC15: human squamous cell carcinoma, tongue (ATCC
CRL-1623)
N SCC9: human squamous cell carcinoma, tongue (ATCC
CRL-1629)
N CAL33: Tongue cancer, elevated EGFR, contact inhibited
tongue cancer (IGBMC cell culture service, Dr Merlin)
N KB: Epidermoid carcinoma, mouth (IGBMC cell culture
service, Dr Merlin)
N HSC2: human squamous cell carcinoma, oral (IGBMC cell
culture service)
N A253: epidermoid carcinoma, submaxillary salivary gland,
(ATCC HTB-41)
N HAN HN2: head and neck tumor (IGBMC cell culture
service).
N RPMI 2650: human squamous cell carcinoma, nasal septum,
quasi-diploid (ATCC CCL-30)
N Det 562: human epithelial carcinoma, pharynx, metastatic
(ATCC CRL-7919)
N Fadu: human squamous cell carcinoma, pharynx, primary,
tumorigenic (IGBMC cell culture service, Dr Merlin)
N Hep 2: epidermoid carcinoma, larynx (ATCC CCL-23)
N MCF7: human caucasian breast adenocarcinoma (ATCC
HTB-22)
N MCF10A: epithelial cell line, mammary gland, non-tumori-
genic. (ATCC CRL-10317)
Quantitative real time PCR (QRT-PCR). Reverse
transcription was performed as described [23]. Briefly, reverse
transcription was performed using 1 mg total RNA, random
primers, and the superscript II RT-PCR system (Life
Technologies). qPCR was performed on 1/50 dilutions of the
CDNA samples using SYBR Green Supermix (qiagen) in a
Applied Biosystems 7500 Real-Time PCR system as described
[24]. All reactions were performed in triplicate. Melting curve
analyses were performed to ensure the specificity of q-PCR.
Primer sets used to test the expression of the two forms of CTIP2
were designed using Primer3 Software. Primers used for mouse
mBmi1 were as described [25]. Data analysis was performed using
the 2
2DDC
t method described previously [26]. Ribosomal
phospho-protein PO (RPLPO) and HPRT was used as reference
gene. qRT-PCR-based gene expression values between the groups
were compared by t test or 1 way ANOVA.
Primers used for Real Time qRT-PCR
CTIP2L(hCTIP2 E2-E3):(F) 59-ATCTGTCCCAAGCAGGA-
GAA-39,( R )5 9-GTCTGACCCTCACCCTGAGT-39; CTIP2(hC-
TIP2 E2-E4):(F)59-AGCAGGAGAACATTGCAGGTA-39,( R ) 5 9-
GGAAATTCATGAGCGGGGACT-39.
Statistical Analysis. The means and standard errors of
qRT-PCR data among different samples were calculated, and the
differences between them were determined by either t test or 1 way
ANOVA, where p,0.05 is regarded as significant.
Results
Expression pattern of CTIP2 in human HNSCC. In order
to localize CTIP2 expression in HNSCC, we performed
immunohistochemistry on paraffin embedded sections of Head
& Neck tumors (n=40) and normal samples (n=12) using high
heat antigen retrieval technique and the previously described
CTIP2 antibody [19,21]. Positive staining for CTIP2 was found to
be exclusively nuclear. Negative control on sections stained
CTIP2 Expression in HNSCC
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mice confirmed no staining [21]. In tumor adjacent normal
epithelium CTIP2 was expressed exclusively by the keratinocytes
of the basal layer and no expression was detected in cells of the
spinous cell layer or granular layer. (Arrows in Fig. 1A, see inset).
In dysplasia samples, CTIP2 expression was stronger compared to
the normal epithelium and also the expression was extended to the
spinous cell layers (Fig. 1B and inset). In well differentiated tumors,
CTIP2 staining was observed in the outer layer of the keratinized
horn-pearls clusters (Fig. 1C and D). Stronger and homogeneous
expression of CTIP2 was observed in moderately and/or poorly
differentiated tumors (Figs. 1E–H) compared to the well
differentiated tumors. We compared the intensities of CTIP2
staining (0–3) (described in materials and methods) between the
adjacent normal, dysplasia and different histological grades of
Head & Neck tumor (Fig. 2A and 2B). Out of the 40 different
samples we analyzed, 12 of them had adjacent normal epithelium
and 4 of them had dysplasia. Compared to normal epithelium,
CTIP2 expression was strongly and significantly up-regulated in
HNSCC samples (P,0.05) (Fig. 2A). The strongest intensity of
CTIP2 staining (level 3) was observed in 11% well differentiated
tumors, 25% of the moderately and in 58% of the poorly
differentiated tumors compared to no staining of this intensities in
adjacent normal epithelium (Fig. 1, Fig. 2A & B and Table 1).
Overall, we observed an increase in the intensity of CTIP2
expression with the progression of carcinoma in all our samples
analyzed. Thus, our IHC results demonstrates that CTIP2
expression is elevated in HNSCC, and that CTIP2 expression is
linked to poor differentiation state of the tumor.
Several reports have shown that polycomb group transcription
factor BMI1, is essential for the self renewal of hematopoietic,
neuronal stem cells as well as cancer stem/progenitor cells
[27,28,29]. We hypothesized that CTIP2 might label and
modulate self renewal of tumor initiating/cancer stem cells in
HNSCC. We therefore performed immunoflourescent co-staining
for CTIP2 and BMI1 protein, in well, moderately and poorly
differentiated HNSCC samples to see if some of the CTIP2
expressing cells also express the cancer stem cell (CSC) marker
BMI1, previously implicated in self renewal and tumorigenesis
[30,31,32,33,34,35,36,37]. Staining for BMI1 was observed mostly
in the basal cell layer and decreased towards the outer cell layers.
In well and moderate to poorly differentiated tumors, majority of
the BMI1 expressing cells showed strong nuclear co-localization of
CTIP2 and BMI1 proteins (CTIP2+/BMI1+) (Fig. 2C & D).
Besides, some of the cancer cells were stained single positive for
CTIP2 (CTIP2+/BMI1
2) (Fig. 2C, inset). Interestingly, qRT-PCR
performed on the CTIP2 mutant mice skin, using mouse specific
Bmi1 primers, showed significant down regulation of Bmi1
expression, suggesting a possible regulation of Bmi1 gene by Ctip2
(Fig. S1) [21]. Furthermore, promoter analyses of mouse and
human BMI1 gene revealed presence of several putative CTIP2
binding sites in the proximal and distal promoter region (data not
shown) [12,14]. Altogether, our results suggest existence of distinct
subsets of cancer cells which express CTIP2 and underscore the
use of CTIP2 and BMI1 co-labeling to identify tumor initiating
cancer stem cells (CSC).
Expression of CTIP2 in human cell lines. CTIP2 protein
expression was detected by western blotting in a panel of cell lines
which included normal, HNSCC and other types of carcinomas
(see material and methods) (Fig. 2E). We detected weak
expressions of CTIP2 in primary human epidermal keratinocytes
(Hek-a) and in spontaneously immortalized non-tumorigenic
human skin keratinocytes (Hacat) [Fig. 2E]. CTIP2 expression
was undetectable in some cell lines from umbilical cord
endothelium (HUVEC), skin and tongue fibroblast (GM3348 &
HS677Tg). In contrast, very high level of CTIP2 was detected in
head and neck cell lines (SCC4, SCC25, HSC2, HAN HN2) and
also in other carcinomas such as epidermoid carcinoma from
submaxillary salivary gland (A253) and breast carcinoma (MCF7)
(see Fig. 2E). Surprisingly, weaker expression was detected in few
Head and neck cell lines such as Det562 and Fadu, and no
expression at all in RPMI 2650. In most of the cases, CTIP2
expression level was lower than our internal control TATA box
binding protein (TBP). Altogether, these results demonstrate that
most of the HNSCC cell lines have increased expression of CTIP2.
Co-labeling of CTIP2 with a proliferation & differentia-
tion marker. To confirm if CTIP2 is linked to the proliferation
and differentiation of HNSCC, we used immunofluorescence
method to co-label CTIP2 with a proliferation (Ki-67) and a
differentiation [cytokeratin 10 (K10)] marker. We observed
cytoplasmic expression of K10 either in clusters or in scattered
areas of the dysplasia samples and also in tumors with well or
moderately differentiated status (Fig. 3A). In dysplasia samples,
most of the supra basal layer cells which were positive for CTIP2
also expressed K10. In well to moderately differentiated tumor
samples with low level of CTIP2 expression, Cytokeratin 10 was
expressed in clusters (Fig. 3A). Some of the CTIP2 positive cells
also expressed K10, and some CTIP2 positive cells were negative
for K10. In poorly differentiated tumors with less differentiation
(less K10 positivity), high levels of CTIP2 was observed which did
not express K10. We have recently shown that CTIP2 colabel with
proliferation marker Ki-67 in normal human skin and in
eczematous skin [38]. In the same line, in our co labeling
experiment in HNSCC, most of the CTIP2 positive cells were also
found to be co-labeled with Ki-67 (Fig. 3B, see double positive
yellow cells). Altogether, our results with K10 and Ki-67 shows
that CTIP2 expression is linked to tumor differentiation state and
proliferation. Poorly differentiated tumors which are less
differentiated contain more proliferative cells, and hence have
higher CTIP2 expression. These results on cytokeratin 10 and Ki-
67 staining pattern confirms that CTIP2 is linked to differentiation
status of the tumor. Less differentiated tumor (poorly differentiated
tumors) express high CTIP2 levels with proliferative nature (colabel
with Ki-67) and express very low levels of cytokeratin K10.
Expression of different CTIP2 transcript in human
HNSCC. Since the CTIP2 antibody we used in our earlier
experiments could not distinguish between the specific CTIP2
isoforms by IHC, we were interested to learn which isoform(s) of
CTIP2 were relevant to HNSCC disease progression by
quantitative real time PCR (qRT-PCR). Human CTIP2 has
three alternatively spliced transcript variants, which encode
distinct isoforms (see Fig. 3A). In our present study, we have
referred CTIP2 with all the 4 exons as CTIP2 long (CTIP2L), the
variant lacking exon3 which is the actual CTIP2 as CTIP2 (Fig. 3A),
and the variant which lacks both Exon2 and 3 as CTIP2 short (not
shown). qRT-PCR was performed for CTIP2L and CTIP2,o n
RNA extracted from 28 different HNSCC samples and
amplifications were normalized using RPLPO as an internal
control. We also included 10 normal uvulas to compare the
expression levels of the transcripts along with HNSCC samples.
To distinguish between the two forms, we have designed specific
primers from exon 2 and exon 3 for CTIP2L, and exon 2 and
overlapping exon 2 and 4 for CTIP2 (see Fig. 3A). The samples
from different tumor size (T size), Tumor staging (T staging) and
differentiation status (see material methods for details) were
divided into early cancer (1–2) and late cancer (2–4),
respectively. A significant number of samples with normal to
high mRNA expression was observed among patients with T1-T4
CTIP2 Expression in HNSCC
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and regional metastasis. However, statistical studies showed no
statistical significance of any correlation between mRNA
expression and any of the clinicopathological parameters with
the CTIP2L (see Fig. 4A and Table 2). On the contrary, there was
a significant correlation of higher CTIP2 expression with a poorer
histological grade of the tumor, and a trend was noted in a
relationship between expression and advanced tumor (T size) or
Figure 1. Immunohistochemical analysis of CTIP2 in HNSCC. (A) Expression in adjacent Normal epithelium is restricted to basal cell layers. (B)
Expression in dysplasia is stronger than normal and extended to differentiated cell layers. (C–D) In well differentiated tumors, positive staining is
restricted to the basal layers at the periphery of the keratinized horn pearl. (E–F) Homogeneous expression of CTIP2 was observed in tumor cells in
moderately differentiated tumors. (G–H) Expression of stronger intensities (score 3) of CTIP2 was observed in poorly differentiated tumors. Arrows
indicates the CTIP2 positive staining. Yellow dotted lines represents the margin of epidermis and dermis (A), and margin of undifferentiated tumor
cell clusters (E) which is magnified in (F). The pictures in the insets (A, B, G and H) are magnified. (Original Magnification: 206).
doi:10.1371/journal.pone.0005367.g001
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results suggest that although both the forms of CTIP2 are elevated
in HNSCC only the actual CTIP2 is linked to the poor
differentiation status of the tumor.
Discussion
In the present study, we demonstrated for the first time over-
expression of transcriptional regulatory protein CTIP2 in head
and neck squamous cell carcinomas using IHC and qRT-PCR
analysis. CTIP2 overexpression was detected in different human
HNSCC cell lines as well as in HNSCC tumor specimens of
different grades and/or differentiation stages. The protein was
detected in several HNSCC cell lines, besides a breast
adenocarcinoma cell line (MCF7), and its expression was
relatively low compared to an internal control. Highest level of
expression was observed in HSC2 (oral) and A253 (salivary gland)
cells, and the lowest in SCC9 and Cal 33 (tongue), KB (mouth),
Hep2 (larynx) and RPMI 2650 (nasal septum). The variation in
the level of expression among different lines may depend on
factors such as tumor stage and/or differentiation status of the
tumor cell lines.
In tumor sections, CTIP2 protein expression was associated
with histological changes such as proliferation and differentiation,
and its increased expression was linked to poorer differentiation
status of those tumors. We were able to detect expression of
CTIP2 protein in normal epithelium and in tumor cells with
HNSCC characteristics within the same tissue sections. Intensities
of staining increased from well, moderately to poorly differentiated
tumors. Dramatic increase in CTIP2 expression was found in
dysplasia where expression was observed all the way up to the
differentiating cell layers, compared to the normal where
expression was restricted to the basal cell layer. We also
determined the expression pattern of the two different isoforms
of CTIP2 [CTIP2L and CTIP2] in progression of HNSCC, using
qRT-PCR analyses and by designing primer specific for each
isoform. Although CTIP2L was elevated in HNSCC, the actual
CTIP2 (CTIP2) was found to be more relevant to the disease
progression. The CTIP2 mRNA level correlated well with the
protein expression level obtained by IHC and western.
It was recently demonstrated that human HNSCC contain
tumorigenic cancer stem cells (CSC) with an ability to self renew
and differentiate [36,39]. In the same line, co-labeling experiments
with CTIP2 and CSC marker BMI1 highlighted the existence of a
distinct subset of cancer cells (BMI1+/CTIP2+) with possible stem
cell characteristics. It has been already shown that CTIP2 is widely
expressed in normal mouse skin [19]. Some, but not all, of the cells
present within hair follicle bulge were also found to co-express
CTIP2, keratin K15, but not CD34, indicating that a subset of
K15+ CD342 skin stem cells may express CTIP2 [19]. It is
possible that CTIP2 might regulate a subset of epithelial stem cell
population in skin as well as in HNSCC. Recent contradictory
Table 1. Staining intensities and percent positivity in normal epithelium and in HNSCC.
A
Staining Intensities
n * 0123
Adjacent Normal 12 2 10 0 0
Dysplasia 4 0121
HNSCC-Well 9 2(23) 3(33) 4(44) 0(0)
HNSCC-Moderately 12 2(17) 4(33) 3(25) 3(25)
HNSCC-Poor 19 2(10) 3(16) 3(16) 11(58)
B
Tumor differentiation Percent positivity
0–25 25–50 50–75 100
Adjacent Normal 12 12 0 0 0
Well 9 6 300
Moderately 1 24 620
Poor 1 95 680
Tumor Stage
Stage I–II 22 14 6 2
Stage III–IV 1 85 670
In brackets are the percentages of specific tumor types.
doi:10.1371/journal.pone.0005367.t001
Figure 2. Staining intensities of CTIP2 by immuno-histochemistry in HNSCC. Staining intensities were 0–3 as described in materials and
method sections. (A) Staining intensities of CTIP2 in normal epithelium (NE), dysplasia and HNSCC. Plotted are mean measurements (6S.E.M).
*p,0.05. (B) Staining intensities in different histological grades of HNSCC. Plotted are mean measurements (6S.E.M). *p,0.05. (C–D) Co-staining of
CTIP2 and BMI1 protein. The insets are magnified. Yellow arrows show the CTIP2 and Bmi1 double positive cells. Yellow arrowhead indicates single
positive cells. (E) CTIP2 expression in HNSCC cell lines by western blot analysis. CTIP2 antibody recognizes the two isoforms (Long and the actual
CTIP2). Green box represents the normal cell lines.
doi:10.1371/journal.pone.0005367.g002
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pattern of CSC marker CD44 in HNSCC has opened up
discussion to identify novel CSC markers in this cancer type.
The present study underscores the possible use of CTIP2 and
BMI1 co-labeling to identify cancer stem cells (CSC) in HNSCC
and suggests a transcriptional regulation of Bmi1 gene by CTIP2.
The mechanisms of differential expression of CTIP2 and
regulation of gene expression by CTIP2 in HNSCC remain to
be elucidated.
CTIP2 protein is already known for its involvement in T-cell
lymphomas and implicated in mouse and human leukemias [40].
CTIP2 is also known to make the DNA more vulnerable to
replication stress and damages, thus being involved in mainte-
nance of genomic stability [41]. Mice with a germ line deletion of
the CTIP2 die after birth and exhibit defects in epidermal
proliferation and terminal differentiation [21]. CTIP2 is also
expressed in human skin and is upregulated in skin from atopic
dermatitis patients [38]. Since CTIP2 has a role in maintenance of
Figure 3. Co-staining of CTIP2, cytokeratin 10 and Ki-67 using immunofluorescence. (A) Co-staining of CTIP2 and differentiation marker
cytokeratin 10 in dysplasia and in moderately differentiated tumor. CTIP2 in green, Cytokeratin 10 in red and DAPI in blue. Yellow dotted lines
represents the margin of epidermis and dermis. (B) Co-staining of CTIP2 and a proliferation marker Ki-67 in poorly differentiated tumor. Insets are in
yellow boxes and are magnified. Yellow arrows shows the CTIP2-Ki-67 double positive cells. (Original Magnification: 206).
doi:10.1371/journal.pone.0005367.g003
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proliferation and differentiation of the tumor cells in HNSCC. In
the present study we found lower CTIP2 expression in more
differentiated tumor type and CTIP2 expression increased with
loss of differentiation. Moreover, most of the Ki-67 positive cells
also were positive for CTIP2, indicating proliferative potential of
CTIP2 positive cells. However, the underlying molecular mech-
anisms and role of this protein in epithelial carcinogenesis is yet
unknown. Mouse models of human cancer play an important role
in understanding the mechanisms of carcinogenesis and have
accelerated the search for finding new molecular targets for cancer
therapy [42]. Therefore, generating transgenic mouse model of
CTIP2 overexpression using epithelial specific promoter would be
a useful tool to study the role of CTIP2 in understanding the
molecular mechanisms of HNSCC development and progression.
Supporting Information
Figure S1 Expression of mouse Bmi1 in Ctip2 mutant
embryonic skin by qRT-PCR. Reduced expression of Bmi1 was
observed in the Ctip2 mutant mice. Plotted are the Relative
quantification levels normalized with HPRT as mean6S.E.M. p
values between wild type and Ctip2 mutant were significant
(p,0.05).
Found at: doi:10.1371/journal.pone.0005367.s001 (0.60 MB EPS)
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Figure 4. Scheme of CTIP2 transcripts and the expression
pattern of CTIP2L and CTIP2 in HNSCC. (A) Two transcripts of human
CTIP2 are shown. CTIP2 with all the 4 exons, is the long form of CTIP2
(CTIP2L), and, lacking exon 3 is the actual CTIP2. Primers for the long
form were taken from Exon 2 for Forward and exon 3 for reverse, and
for the shorter form, the forward from boundary of Exon 2 & 4 and the
reverse from exon 4. Expression of the CTIP2 long (B) and CTIP2 (C), by
qRT-PCR in HNSCC (n=28) and 10 normal uvulas based on T size, Tumor
staging, and differentiation status. Plotted are the Relative quantifica-
tion levels normalized with RPLPO as S.E.M6. p values were not
significant between the groups in (B) but a significant correlation of
higher CTIP2 expression was observed with a poorer histological grade
of the tumor, and a trend was noted in a relationship between
expression and advanced T or clinical stage in (C) [P,0.05].
doi:10.1371/journal.pone.0005367.g004
Table 2. Correlation between CTIP2 mRNA expression levels
and Clinicopathological characteristics in HNSCC.
Total
Total CTIP2L CTIP2
All cases 28 P value P value
Tumor differentiation status t test 0.734 0.0439
Well-Moderately 18
Poor-Undifferentiated 10
Tumor location 1 way anova 0.0716 0.2476
Hypopharynx 8
Oral cavity 10
oropharynx 6
larynx 4
Tumor size t test 0.8394 0.5511
T1–T2 19
T3–T4 9
N Stage t test 0.6697 0.9862
N0 13
N+ 15
Tumor Staging t test 0.6737 0.3217
I–II 9
III–IV 19
Statistical analysis was performed as described in material and methods
sections.
doi:10.1371/journal.pone.0005367.t002
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